GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone240-243-1201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
Employees50
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) announced its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.01. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
5 analysts have issued twelve-month price objectives for GlycoMimetics' stock. Their predictions range from $20.00 to $35.00. On average, they anticipate GlycoMimetics' share price to reach $25.50 in the next twelve months. This suggests a possible upside of 114.8% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
What are Wall Street analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
- 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (5/8/2019)
- 2. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)
Has GlycoMimetics been receiving favorable news coverage?
Headlines about GLYC stock have been trending positive on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GlycoMimetics earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Akcea Therapeutics (AKCA), Insmed (INSM), Arrowhead Pharmaceuticals (ARWR), Portola Pharmaceuticals (PTLA), Endocyte (ECYT), Xencor (XNCR), Allakos (ALLK), AnaptysBio (ANAB), Tricida (TCDA), Pacira Biosciences (PCRX), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Nabriva Therapeutics (NBRV) and Zai Lab (ZLAB).
What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 60)
- Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
- Mr. Henry Flanner, VP of Technical Operations
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (11.50%), OppenheimerFunds Inc. (11.02%), FMR LLC (9.02%), BlackRock Inc. (6.69%), Redmile Group LLC (4.67%) and Jennison Associates LLC (3.30%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which institutional investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Citigroup Inc., Janus Henderson Group PLC, Man Group plc, Morgan Stanley, Wells Fargo & Company MN, TD Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold GlycoMimetics company stock in the last year include Brian M Hahn and John L Magnani. View Insider Buying and Selling for GlycoMimetics.
Which institutional investors are buying GlycoMimetics stock?
GLYC stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Dimensional Fund Advisors LP, Asymmetry Capital Management L.P., Candriam Luxembourg S.C.A., BlackRock Inc., Redmile Group LLC, Geode Capital Management LLC and Jefferies Group LLC. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $11.87.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $512.55 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.
What is GlycoMimetics' official website?
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
